WHITEHAWK THERAPEUTICS INC (WHWK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.60-0.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · WHWK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -45.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 37.7% |
Growth built into the price is above our model estimate.
The price assumes 83.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
WHWK — capital allocation — Unregistered Sales of Equity Securities The information in
Dated 2026-05-13
Unregistered Sales of Equity Securities The information in
Why it matters: Better management of costs leads to smaller operating losses. This can help investor confidence.
Supportive ifOperating income improves further from -$23.5M in Q1 2026.
Worry ifOperating losses worsen or fail to improve from -$23.5M in Q1 2026.
Why it matters: Details on the PIPE financing can impact cash flow and investor confidence. Clarity on funding is essential.
Supportive ifManagement shares good news on the PIPE financing. This confirms a successful capital raise.
Worry ifBad news or delays about the Securities Purchase Agreement come out.
Why it matters: This submission is important for Whitehawk's ADC pipeline. It will help attract investors.
Supportive ifThe company submits the IND application for HWK-206 by mid-2026 as planned.
Worry ifThe IND submission for HWK-206 is delayed beyond mid-2026.
Why it matters: Stable or rising revenue is important for long-term growth and investor trust.
Supportive ifRevenue stabilizes or increases from $0 in Q1 2026.
Worry ifRevenue continues to decline or remains at $0 in subsequent quarters.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $677 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,824 loss on $10,000 · 28.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial is key for Whitehawk's ADC pipeline. It shows progress in their drug development.
Supportive ifThe Phase 1 trial for HWK-206 begins as planned in Q3 2026.
Worry ifThe trial does not start in Q3 2026 as indicated.
Why it matters: Closing this financing is important for Whitehawk's cash runway. It will help fund operations.
Supportive ifThe PIPE financing closes successfully. It provides $87.5 million in funding.
Worry ifThe PIPE financing does not close due to unmet conditions.
Why it matters: This agreement could greatly increase Whitehawk's ADC pipeline. It shows their plan to improve products.
Supportive ifWhitehawk shares new ADC programs from the Hangzhou DAC agreement.
Worry ifNo new programs are announced or the agreement is terminated.
Why it matters: Extending the cash runway shows management is working on liquidity. This is key for survival.
Supportive ifCash runway extends into the second half of 2028 with new financing.
Worry ifManagement does not secure financing, which shortens the cash runway a lot.
Why it matters: Legal case results can impact money matters. They also affect investor confidence.
Worry ifDetails of the legal case may show a positive result or solution.
Less concerning ifLitigation gets worse or leads to big financial penalties.
Why it matters: Sustaining revenue is key for growth. A rebound would show progress in management's efforts.
Watch forRevenue generation returns to at least $7.1M in Q2 2026.
Also watch forRevenue stays at $0, showing a continued decline.
Why it matters: Lawsuit results can change how the company makes money. They also affect how management focuses. This can influence how investors feel.
Worry ifUpdates show that the company wins its lawsuits. This is good news for the company.
Less concerning ifNegative news in lawsuits that hurt the company's legal position.
Why it matters: Controlling cash burn is key for Whitehawk's finances. Better management shows they are controlling costs.
Supportive ifResearch and development costs keep going down or staying steady at lower amounts.
Worry ifCash burn rates go up a lot or stay high without good reason.
Why it matters: Completion will show progress in Whitehawk's ADC pipeline. It may lead to future approvals.
Supportive ifBoth Phase 1 trials for HWK-007 and HWK-016 are completed as scheduled.
Worry ifOne or both Phase 1 trials for HWK-007 and HWK-016 are delayed or halted.
Why it matters: Data from these trials will show how effective the treatments are. This is crucial for future funding and development.
Supportive ifInitial results from HWK-007 and HWK-016 are reported in 1H 2027.
Worry ifInitial results are delayed beyond 1H 2027.
Why it matters: These applications show Whitehawk wants to grow its pipeline. This could bring in more money.
Supportive ifWhitehawk submits IND applications for multiple new ADC programs in the next 12-24 months.
Worry ifNo IND applications are submitted on time.
Why it matters: This partnership may improve Whitehawk's ADC pipeline. Good news could help investors feel better.
Watch forNew programs or good news from the Hangzhou DAC partnership.
Also watch forNo news or bad updates about the partnership.